Table 2 Cervical lesion, management and follow up of HIV negative and positive women
Evaluated population N = 292d | HIV − (N = 146) | HIV + (N = 146) | P value | |
|---|---|---|---|---|
Baseline pap-test | 286 | N = 140 (100%) | N = 146 (100%) | 0.010b |
Normal | 1 | 0 (0%) | 1 (0.7%) | |
LSIL | 90 | 38 (27.1%) | 52 (35.6%) | |
HSIL | 152 | 73 (52.1%) | 79 (54.1%) | |
ASCUS | 35 | 22 (15%) | 14 (9.6%) | |
ASCH | 7 | 7 (5%) | 0 (0%) | |
Cancer | 1 | 1 (0.7%) | 0 (0%) | |
HPV | 141 | N = 42 | N = 99 | 0.325b |
Negative | 9 | 2 (4.8%) | 7 (7.1%) | |
HR HPV | 108 | 31 (73.8%) | 77 (77.8%) | |
HPV 16/18 | 8 | 5 (11.9%) | 3 (3%) | |
HPV other than 16/18 | 13 | 3 (7.1%) | 10 (10.1%) | |
HPV 16 and other | 3 | 1 (2.4%) | 2 (2%) | |
Baseline biopsy | 284 | N = 140 (100%) | N = 144 (100%) | 0.856b |
Normalc | 4 | 2 (1.4%) | 2 (1.4%) | |
LSILc | 3 | 2 (1.4%) | 1 (0.7%) | |
HSIL | 277 | 136 (97.1%) | 141 (97.9%) | |
Vaccination | 280 | N = 134 | N = 146 | 0.791b |
Unvaccinated | 80 | 40 (29.8%) | 40 (27.4%) | |
Vaccinated | 17 | 9 (6.7%) | 8 (5.5%) | |
Not reported | 183 | 85 (63.4%) | 98 (67.1%) | |
Treatment | 292 | N = 146 (100%) | N = 146 (100%) | 0.290b |
Follow-up | 27 | 12 (8.2%) | 15 (10.3%) | |
Conisation | 172 | 94 (64.4%) | 78 (53.4%) | |
Ablative treatment or local therapy | 85 | 37 (25.3%) | 48 (32.9%) | |
Hysterectomy | 8 | 3 (2%) | 5 (3.5%) | |
Persistence | 292 | N = 146 (100%) | N = 146 (100%) | < 0.001b |
No | 207 | 122 (83.5%) | 85 (58.2%) | |
Yes | 85 | 24 (16.5%) | 61 (41.8%) | |
Type of persistence | 85 | N = 24 (100%) | N = 61 (100%) | 0.072b |
CIN1 | 32 | 9 (37.5%) | 28 (45.9%) | |
CIN2/CIN3 | 35 | 10 (41.6%) | 29 (47.5%) | |
ASCUS HPV + | 5 | 4 (16.6%) | 1 (1.6%) | |
ASCH | 4 | 1 (4.3%) | 3 (5%) | |
Recurrence | 292 | N = 146 (100%) | N = 146 (100%) | 0.18b |
No | 277 | 136 (93.1%) | 141 (96.5%) | |
Yes | 15 | 10 (6.9%) | 5 (3.5%) | |
Time of follow-up (in weeks) | ||||
Median (IQR) | 292 | 142 (62–304) | 165 (48–444) | 0.112a |